• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by LB Pharmaceuticals Inc

    4/23/26 4:10:35 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBRX alert in real time by email
    DEFA14A 1 d269343ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

    LB Pharmaceuticals Inc

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    Your Vote Counts! LB PHARMACEUTICALS INC 2026 Annual Meeting of Stockholders Vote by June 2, 2026 11:59 PM ET LB PHARMACEUTICALS INC ONE PENNSYLVANIA PLAZA, SUITE 1025 NEW YORK, NY 10119 V95415-P50676 You invested in LB PHARMACEUTICALS INC and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2026 at 9:30 a.m. Eastern Time, at www.virtualshareholdermeeting.com/LBRX2026 and any adjournment or postponement thereof. Get informed before you vote View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 3, 2026 9:30 a.m. Eastern Time vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/LBRX2026 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting as described in the more complete proxy materials that are available to you on the Internet. Please follow the instructions on the reverse side to vote these important matters. Before voting, we encourage you to access and review all of the important information contained in the proxy materials. Board Voting Items Recommends 1. To elect three nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders. Nominees: For 01) Robert A. Lenz M.D., Ph.D. 02) Rebecca Luse 03) Ran Nussbaum 2. To ratify the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s For independent registered public accounting firm for the fiscal year ending December 31, 2026. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments or postponements thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V95416-P50676

    Get the next $LBRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LBRX

    DatePrice TargetRatingAnalyst
    4/10/2026$36.00Buy
    Craig Hallum
    1/9/2026Buy
    Roth Capital
    10/6/2025$27.00Buy
    Stifel
    10/6/2025$78.00Overweight
    Piper Sandler
    10/6/2025$34.00Outperform
    Leerink Partners
    More analyst ratings

    $LBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on LB Pharmaceuticals with a new price target

    Craig Hallum initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $36.00

    4/10/26 8:41:05 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on LB Pharmaceuticals

    Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy

    1/9/26 9:05:22 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on LB Pharmaceuticals with a new price target

    Stifel initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $27.00

    10/6/25 8:30:35 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by LB Pharmaceuticals Inc

    DEFA14A - LB PHARMACEUTICALS INC (0001691082) (Filer)

    4/23/26 4:10:35 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by LB Pharmaceuticals Inc

    DEF 14A - LB PHARMACEUTICALS INC (0001691082) (Filer)

    4/23/26 4:06:50 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by LB Pharmaceuticals Inc

    EFFECT - LB PHARMACEUTICALS INC (0001691082) (Filer)

    4/15/26 12:15:13 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lenz Robert A.

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    3/10/26 4:19:34 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lenz Robert A.

    3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    3/10/26 4:16:37 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    2/10/26 4:30:04 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

    Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled "Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizo

    4/22/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

    NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner, Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:45 a.m. ET. A live webcast of the presentation will be available on the "Investors" page under the "Events" section of the Company's website at https://ir.lbpharma.us/investors/events/, where a replay of the webcast will b

    4/9/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

    NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic

    3/27/26 12:00:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Deep Track Biotechnology Master Fund, Ltd. converted options into 686,138 shares and bought $39,999,990 worth of shares (2,666,666 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 6:09:13 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussbaum Ran converted options into 411,681 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:05 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Pontifax Management 4 G.P. (2015) Ltd. bought $15,000,000 worth of shares (1,000,000 units at $15.00) and converted options into 411,681 shares (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:07 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Leadership Updates

    Live Leadership Updates

    View All

    LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals

    3/9/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg

    1/21/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

    NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea

    1/6/26 7:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care